Company Encyclopedia
View More
name
Carlisle Cos
CSL.US
Carlisle Companies Incorporated operates as a manufacturer and supplier of building envelope products and solutions in the United States, Europe, North America, and internationally. It operates through two segments, Carlisle Construction Materials (CCM) and Carlisle Weatherproofing Technologies (CWT). The CCM segment offers single-ply roofing solutions, including ethylene propylene diene monomer, thermoplastic polyolefin, polyvinyl chloride membrane, polyiso insulation, and engineered metal roofing and wall panel systems for commercial and residential buildings. Its CWT segment provides waterproofing and moisture protection products; protective roofing underlayment; fully integrated liquid and sheet applied air/vapor barriers; sealants/primers and flashing systems; roof coatings and mastics; spray polyurethane foam and coating systems for a range of thermal protection applications and other premium polyurethane products; block-molded expanded polystyrene insulation; engineered products for HVAC applications; and products for a variety of industrial and surfacing applications.
518.50 B
CSL.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Building ProductsIndustry
Industry Ranking26/49
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE32.39%A
    • Profit Margin15.48%A
    • Gross Margin36.02%C
  • Growth ScoreD
    • Revenue YoY0.14%C
    • Net Profit YoY-42.73%D
    • Total Assets YoY-0.34%D
    • Net Assets YoY-27.91%E
  • Cash ScoreC
    • Cash Flow Margin647.36%C
    • OCF YoY0.14%C
  • Operating ScoreB
    • Turnover0.78B
  • Debt ScoreD
    • Gearing Ratio69.15%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    1832 Asset Management L.P. Sells 4,863 Shares of Carlisle Companies Incorporated $CSL

    1832 Asset Management L.P. reduced its stake in Carlisle Companies Incorporated by 4.5% in the 2nd quarter, selling 4,863 shares. The firm now owns 102,252 shares worth $38.18 million. Several other institutional investors also adjusted their positions in Carlisle Companies. Analysts have mixed ratings on the stock, with a consensus target price of $386.67. Carlisle Companies reported Q3 earnings of $5.61 per share, beating estimates, with revenue of $1.35 billion. The company announced a quarterly dividend of $1.10 per share.

    Market Beat·
    US
    CSL
    +0.50%
    Market Beat·
    US
    CSL
    +0.50%

    Morgan Stanley Sticks to Their Buy Rating for CSL (CMXHF)

    Morgan Stanley analyst David Bailey maintained a Buy rating on CSL, setting a price target of A$256.00. Bailey, a 4-star analyst with a 10.1% average return, focuses on the Healthcare sector. The general analyst consensus for CSL is a Strong Buy with a $159.89 average price target.

    Tip Ranks·
    US
    CSL
    +0.50%
    Tip Ranks·
    US
    CSL
    +0.50%

    BUZZ-Morningstar sees Australia's CSL as 'cheap', optimistic for margin rebound

    Morningstar views Australia's CSL as undervalued despite a 40% drop in shares since acquiring Vifor in August 2022. The acquisition has diluted ROIC, but Morningstar expects improvement to pre-acquisition levels. CSL's current plasma product pipeline is slim, but margins are expected to rebound due to restructuring and new high-margin products. The fair value estimate remains at A$295.

    Reuters·
    US
    CSL
    +0.50%
    Reuters·
    US
    CSL
    +0.50%

    CSL to pump $1.5bn into US plasma supply chain

    CSL plans to invest $1.5bn in the US over five years to expand its plasma therapy production, reflecting the growing need for immunoglobulin. The investment aims to create hundreds of American jobs and strengthen CSL's plasma-derived therapies manufacturing. CSL Behring, headquartered in Pennsylvania, generated $11.16bn in revenue in 2024, with its Ig portfolio growing by 7%. The expansion aligns with the US onshoring manufacturing push amid tariff threats.

    Pharmaceutical Technology·
    US
    CSL
    +0.50%
    Pharmaceutical Technology·
    US
    CSL
    +0.50%

    CSL To Invest $1.5 Bln In U.S. To Manufacture Plasma-Derived Therapies

    Nov 18 (Reuters) - CSL Ltd (CSL.AX) :* TO INVEST APPROXIMATELY $1.5B IN U.S. TO MANUFACTURE PLASMA-DERIVED THERAPIES Further company coverage: (CSL.AX)

    Reuters·
    US
    CSL
    +0.50%
    Reuters·
    US
    CSL
    +0.50%
    © 2025 Longbridge｜Disclaimer